By allowing ads to appear on this site, you support the local businesses who, in turn, support great journalism.
gbtribune news logo anvil app gbtribune news logo anvil app
Genzada Pharmaceuticals announces FDA clearance of IND application and launch of Phase I human clinical trial for Middle Eastern-Derived advanced cancer drug
STERLING — Genzada Pharmaceuticals USA Inc., a subsidiary of Ionics Life Sciences Limited (Genzada), announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for a Phase 1 human clinical trial of the company’s flagship molecule GZ17-6.02 (6.02) for patients with advanced solid organ tumors or lymphoma.
Sponsor Ad
Run of Site Anvil